Fennec Pharmaceuticals Posts 73% Revenue Growth, PEDMARK Demand Hits Record: Key Insights from Q1 2026

PEDMARK Drives Record Revenue: First Quarter 2026 Sees 73% Year-Over-Year Growth

Fennec Pharmaceuticals kicked off 2026 with a remarkable surge in momentum, reporting net revenues of $15.1 million for the first quarter—up 73% from the same period last year. This impressive growth was fueled by accelerating demand for PEDMARK®, the company’s flagship therapy for preventing hearing loss in pediatric cancer patients treated with cisplatin.

Field Force Expansion and Clinical Studies Set the Stage for Growth

Fennec’s recent sales and field expansion is already showing results, with April 2026 marking record levels of PEDMARK demand. Adoption continues to deepen among existing and new prescribers, particularly in core cancer types such as testicular, cervical, and head and neck cancers. The company’s comprehensive patient services (the Fennec HEARS® HUB) has also played a substantial role in driving higher utilization rates and improving patient experiences.

On the clinical front, Fennec initiated a new investigator-sponsored study evaluating PEDMARK in adolescent, young adult (AYA), and adult patients with head and neck or testicular cancers. Additionally, four new abstracts focused on PEDMARK will be featured at the 2026 ASCO Annual Meeting, further solidifying clinical interest in broadening the therapy’s reach.

Financial Metrics Highlight Stability and Strategic Investments

First quarter 2026 financial results show a company investing aggressively in commercial growth while maintaining a strong balance sheet. Sales and marketing expenses rose by $8.2 million year-over-year, reflecting higher commercialization spending and an expanded sales team. However, general and administrative costs were cut by $2.68 million, due in part to reduced legal and professional fees.

*December 31, 2025

Balance Sheet Signals Ample Resources for 2026 Expansion

Fennec ended the quarter with $40.18 million in cash and equivalents, up from $36.79 million at year-end 2025—a reflection of both positive operating cash flow and cash inflows from option exercises. The company projects its current resources, plus ongoing PEDMARK sales, will be sufficient to support its operating plans throughout 2026.

PEDMARK: Expanding Therapeutic Footprint and Market Opportunity

PEDMARK remains the only FDA-approved therapy targeting the reduction of ototoxicity from cisplatin in pediatric oncology, and now clinical studies are investigating broader cancer populations. With approximately 500,000 new U.S. cancer cases annually eligible for platinum-based chemotherapy, the long-term potential for PEDMARK and its European counterpart (PEDMARQSI®) is significant.

In March 2024, Fennec inked an exclusive licensing agreement enabling commercialization in Europe, the U.K., Australia, and New Zealand. PEDMARK and PEDMARQSI benefit from robust patent protections lasting through 2039 and are recognized by key clinical guidelines in both the U.S. and Europe.

Upcoming Catalysts in Q2 2026: Investor Events and ASCO Data

Fennec has a busy calendar ahead: new data from institution-led studies, high-profile investor conferences, and four featured abstracts at the June 2026 ASCO Annual Meeting will keep the company front and center for investors. The virtual annual meeting for shareholders is scheduled for June 10, 2026.

Takeaway: Strategic Positioning and Growing Clinical Validation Poise Fennec for Sustained Momentum

With record revenue growth, increasing institutional interest in PEDMARK, and a solid cash foundation, Fennec Pharmaceuticals appears well-positioned for continued momentum through 2026. Investors eyeing the company’s next moves should watch for clinical data updates at ASCO and signals of commercial progress in both U.S. and international markets as the year advances.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI